前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响

doi:10.3969/j.issn.1006-6233.2017.12.008

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1385 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore clinical efficacy and serum inflammatory factor use of alprostadil combined with telbivudine in treatment of hepatitis B virus-related cirrhosis,providing a theoretical basis for clinical treatment. Methods:98 patients with hepatitis B cirrhosis admitted in our hospital from June 2014 to June 2016, were selected. According to the random number table, patients were divided into telbivudine group (49 cases) and combined group (49 cases). On the basis of routine treatment, telbivudine group was given telbivudine, combined group was given telbivudine and alprostadil for 12 weeks. To observe and analyze the changes of serum HBV DNA levels, liver function and serum inflammatory factor. Results:After treatment, overall efficacy of combined group was significantly higher than that of telbivudine group (89.30% VS.63.89%,P< 0.05).After treatment, the serum HBV and DNA levels of the two groups were significant lower than those before treatment,but there was no significant difference (P>0.05) between two groups. After treatment, serum AST, ALT, Tbil, IL-6, IL-22 and hs-CRP levels of combined group were significantly lower than those of telbivudine group (P<0.05). Conclusion:Alprostadil combined with telbivudine could reduce serum HBV DNA levels, improve liver function, and alleviate the inflammatory condition of patients with ghepatitis B virus-related cirrhosis.

Key words： Alprostadil Telbivudine Hepatitis B virus-related cirrhosis Inflammatory factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xun
	LIU Haibin

Cite this article:

CHEN Xun,LIU Haibin. Effects of Alprostadil Combined with Telbivudine on Clinical Efficacy and Serum Inflammatory Factor in Patients of Hepatitis B Virus-related Cirrhosis[J]. HeBei Med, 2017, 23(12): 1963-1965.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.12.008 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I12/1963

[1] 康瑜,陈建芳,曾甜.慢性乙型肝炎肝硬化患者Th22细胞和IL-22的表达及意义[J].免疫学杂志,2017,33(2):147~151.
[2] 雷子庆,张鑫.替诺福韦和恩替卡韦治疗乙型肝炎肝硬化的疗效对比[J].分子影像学杂志,2016,39(4):383~386.
[3] Huang SS, Xie DM, Cai YJ, et al. C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis: time-dependent receiver operating characteristics and decision curve analysis[J].Eur Gastroenterol Hepatol,2017,29(4):472~480.
[4] 赵红霞,周建华,张宏宇.慢性乙肝患者血清大蛋白表达及其与Th1/Th2细胞因子水平的关系[J].山东医药,2014,54(26):43~45.
[5] 刘浩.前列地尔联合替米沙坦治疗糖尿病肾病疗效观察[J].蚌埠医学院学报,2016,41(7):861~862,865.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防冶指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13~14.
[7] 吴松柏,暴宏伶,艾素玲,等.益气解毒软肝汤治疗乙型肝炎后肝硬化38例[J].中国实验方剂学杂志,2013,19(21):285~289.
[8] 李国焕,舒盼,张均倡,等.恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎肝硬化疗效观察[J].实用肝脏病杂志,2015,18(6):616~619.
[9] 李广明,赵小丽,胡善雷,等.替比夫定治疗慢性乙型肝炎病毒感染孕妇的安全性及有效性评价[J].中华医院感染学杂志,2014,24(9):2169~2171.
[10] 王忠琼,刘翼,夏国栋,等.前列地尔对乙肝肝硬化患者血清炎性因子及肝功能的影响[J].医学研究生学报,2017,30(6):611~614.
[11] 李慧丽,卢雪峰,李娜.恩替卡韦联合前列地尔治疗乙型肝炎肝硬化腹水的效果观察[J].临床肝胆病杂志,2016,32(2):292~295.
[12] 郑建敏.替比夫定与前列地尔联和治疗慢性乙型肝炎肝硬化的临床疗效观察[J].现代实用医学,2014,26(6):722~724.
[13] 周全,李海霞,王丽,等.疏肝健脾汤对早期乙肝肝硬化患者血清炎性因子的影响[J].中药材,2017,40(4):961~963.